Abbvie Inc
NYSE: ABBV
$177.84
+$0.89 (+0.5%)
Real Time Data Delayed 15 Min.
ABBV Articles
Credit Suisse is adding some top conservative dividend-paying stocks to its Top Picks list, and that is right in line with what other top Wall Street firms are doing.
Published:
The September 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has increased.
Published:
The short interest data have been released for the August 31 settlement date, and for the selected pharmaceutical stocks, short interest is mixed.
Published:
ThinkstockAbbVie Inc. (NYSE: ABBV) has continued to push forward over the past year and shares are actually up 7.3% in the past 52-weeks despite the markets pulling back in August. Late Thursday, the...
Published:
Last Updated:
The August 14 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
Published:
ThinkstockWith a very nervous market, and the end of summer doldrums upon us, it may be time to look for ideas that will make sense when the market heats back up in the fall. One area that looks very...
Published:
The short interest data have been released for the July 31 settlement date, and for most of the selected pharmaceutical stocks, short interest decreased.
Published:
Independent research firm Argus has maintained its Buy rating and its $85.00 price target on AbbVie.
Published:
ThinkstockThe short interest data have been released for the July 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market...
Published:
Last Updated:
AbbVie reported better-than-expected second-quarter financial results Friday before the markets opened.
Published:
Abbvie is scheduled to report its second-quarter financial results before the markets open Friday.
Published:
Earnings season is hitting its stride next week, and the health care sector, the biotech stocks in particular, have been on a roll for the past 12 months.
Published:
Last Updated:
A new report from Jefferies updates the firm's top global pharmaceutical stocks to buy, and these picks make sense for investors now.
Published:
The June 30 short interest data have been compared with the previous figures, and across the selected pharmaceutical stocks, short interest decreased.
Published:
A new report from UBS highlights three stocks that the firm likes best now. Not only do they all pay a solid dividend and have a good potential for growth, they all could help cushion a portfolio...
Published: